Company Overview and News
Dividend growth stocks have taken it on the chin in October. That’s especially true of S&P 500 tech sector stocks. Only consumer discretionary and materials stocks have done worse over the same period.
HBANN HBANO F HBANP CIB MC HMC HBAN APAM LULU VZ GM
The widely expected interest rate hike was announced at the end of the two-day Federal Reserve Open Market Committee (FOMC) meeting yesterday. The federal funds rate, increased for the third time this year, now stands at 2-2.25%. At present, the rate is at the highest level in a decade. Despite this, majority of the finance sector stocks ended the day in red, dragging down the S&P 500. Notably, the S&P 500 Financial (sector) and the S&P 500 Bank (Industry Group) indexes were down 1.
GFN HBANN GFNCP HBANO HBANP MBFI WTFCW WTFPP MBFIP WTFC GFNSL HBAN WTFCM FCB GFDV KBE
In the Q2 earnings season, the Finance sector turned out to be one of the best performers. Particularly, benefits from a stabilizing economy and improving interest-rate scenario have well positioned the banking industry. Moreover, lower commercial tax rate are likely to boost banks’ profitability further. In addition, relieving banks from some of the stringent requirements of the Dodd-Frank Act has made the companies optimistic of future earnings growth and raised investors’ sentiments as well.
HBAN HBANN HBANO HBANP TCBI BOKF FFIN
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
HBAN HBANN HBANO HBANP
Investors looking for stocks in the Banks - Midwest sector might want to consider either Huntington Bancshares (HBAN - Free Report) or Lakeland Financial (LKFN - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
HBAN HBANN LKFN HBANO HBANP
Of late, the finance sector has been putting up an impressive performance, with some monthly volatility. The United States’ economic health, on which this sector is largely dependent, has been displaying steady improvement with increasing real GDP numbers, declining unemployment rate, improving consumer spending and stabilizing housing market. A stronger-than-expected U.S. payroll data released last week has raised expectations for the Fed interest rate hike in September — the third this year.
HBAN HBANN HBANO HBANP STI CMA STI-A MPC
It has been about a month since the last earnings report for Huntington Bancshares (HBAN - Free Report) . Shares have added about 5.7% in that time frame, outperforming the S&P 500.
HBAN HBANN HBANO HBANP
2018-08-18 seekingalpha - 2
Today's Idea Guide looks at a few ideas on companies whose futures seem to be pointed in one direction, to see if the market is right or just overreacting.
HBANN HBANO FIT HBANP LUB GOLF MANU HBAN GPRO ZNGA DRYS VALU AAPL DCIX KHC SND
2018-08-03 investorplace - 1
It took some coaxing, but when push came to shove later on the day on Thursday, it was the bulls doing most of the shoving. The S&P 500 ended the day at 2827.22, up 0.49%, led by Apple (NASDAQ:AAPL) and Advanced Micro Devices (NASDAQ:AMD). The technology trade is back “on,” and those two names have been the most reliable leaders of late.
HBAN GPRO HBANN HBANO HBANP AAPL FCX RCL AMD
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
HBAN CWH HBANN HBANO HBANP
Document Table of Contents
Greetings and welcome to the Huntington Bancshares' Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
HBAN HBANN HBANO HBANP DB MS
Huntington Bancshares (HBAN - Free Report) reported second-quarter 2018 earnings per share of 30 cents, beating the Zacks Consensus Estimate by a penny. Also, the figure came in higher than the prior-year quarter adjusted earnings of 26 cents.
HBANN SBNY HBANO HBANP DB WBSFW SBNYW RF HBAN WBS CIT
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HBAN / Huntington Bancshares, Inc. on message board site Silicon Investor.
|HBAN - Huntington Bancshares||HBAN - Huntington Bancshares||HBAN - Huntington Bancshares|
as of ET